Compare Novavax Inc (NVAX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Synchrony Financial — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Synchrony Financial trades at $72.8 (market cap $23.99B). The key difference: Synchrony Financial is far larger — about 13.2× Novavax Inc's market cap, and Synchrony Financial pays a 1.84% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Synchrony Financial for 29 Days on average.
| NVAX | SYF | |
|---|---|---|
Market Cap | $1.82B | $23.99B |
Volume | 6,198,505 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $12.75 | $88.47 |
52-Week Low | $6.22 | $63.78 |
Typical Hold Time | 59 Days | 29 Days |
Enterprise Value | $1.39B | $24.23B |
Dividend Yield | — | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Synchrony Financial (SYF) trades at $73.72, up 2.49% on the day, with a bullish technical signal despite some bearish moving average indicators. The stock shows strong fundamentals with a low P/E of 7.56, robust net income margin of 23.4%, and consistent earnings beats in recent quarters. Recent developments include a partnership with OpenAI to enhance AI-driven shopping and expansion of CareCredit's veterinary financing via Vetspire, signaling growth initiatives.
The outlook remains positive given attractive valuation, high profitability, and analyst consensus price target of $87.58 implying ~19% upside. Key risks include rising credit delinquencies industry-wide and volatile cash flow trends, with net cash flow turning negative in 2026. Institutional sentiment is bullish with 61% buy ratings, but investors should monitor consumer spending resilience and Q3 2026 earnings due October 20.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
